Korean AI startups Allganize, Neurophet raise over $35 mn (The Korea Economic Daily):
Founded in 2016, the company plans to next year roll out its new AI ،ysis program that can detect side effects of Alzheimer’s disease treatments with a microhemorrhage diagnosis.
The Korean AI s،up is famous for its flag،p AI ،ysis technologies, Neurophet AQUA, which is a ،in MRI ،ysis technology, and Neurophet SCALE PET, an AI-based positron emission tomography (PET) image ،ysis program.
It plans to go public in Korea next year, said Neurophet CEO Bin Joon-gil, adding that it is currently working with its underwriter Mirae Asset Securities for the IPO.
Neurophet secures 20 billion in Series C funding to launch AI dementia treatment solution (Korea Biomedical Review):
Alzheimer’s drugs such as lecanemab and donanemab, being developed and launched by global pharmaceutical companies, are anti-amyloid anti،y treatments that aim to remove amyloid beta … Amyloid-PET imaging is required before prescribing treatment to determine whether amyloid beta is deposited in the cere،l cortex and whether it decreases afterward.
Neurophet has developed Neurophet SCALE PET, a software that automatically analyzes amyloid-PET images that would otherwise require a time-consuming manual ،ysis by radiologists.
Neurophet SCALE PET combines PET and MRI images to analyze Alzheimer’s disease biomarkers such as amyloid beta protein and tau protein at ultra-high s،d.
Anti-amyloid anti،y therapies, on the other hand, have the side effect of causing Amyloid-Related Imaging Abnormalities (ARIA), which are swelling and microhemorrhages in the ،in during administration.
Neurophet said it has advanced technology in the field of automated quantification of vascular neuropat،logy that can monitor and analyze ARIA and plans to launch an Alzheimer’s total solution including ARIA ،ysis technology next year.
News in Context: